On September 14, 3SBIO rose 5.31% in regular trading, trading at HKD 16.27 per share, with turnover of approximately HKD 140 million. The rally was primarily fueled by a series of aggressive share buybacks and an insider purchase by the company's executive director and chairman.

On the corporate action front, 3SBIO repurchased 4 million shares on September 10 at prices ranging from HKD 15.50 to HKD 15.75, spending approximately HKD 62.63 million, followed by another 190,000 shares on September 11 at HKD 15.13–15.17 for about HKD 2.88 million. Meanwhile, executive director and chairman Lou Jing purchased 490,000 shares on September 7 at HKD 16.00 per share, raising his long position to 21.13%. The company has cumulatively repurchased over 13.19 million shares under its buyback mandate authorized in June, out of a total authorization of approximately 253.7 million shares.

The broader biotechnology sector provided additional tailwinds, with AKESO gaining 6.59% and INNOVENT BIO rising 2.35% during the same session. Multiple brokerages maintain bullish ratings on 3SBIO, citing the global clinical advancement of its 707 pipeline asset with Pfizer as a key medium-term catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)